Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions

Cancer Letters

Volumn 336, Issue 2, 2013, Pages 299-306

  Kennedy, Colin R ^a   Tilkens, Sarah B ^a   Guan, Hong ^a   Garner, Justine A ^a   Or, Penelope M Y ^b   Chan, Andrew M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Glioblastoma; Metabolism; PI3 K; Warburg's effect

Indexed keywords

DEOXYGLUCOSE; OLIGOMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; MIGRATION INHIBITION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DEOXYGLUCOSE; GLIOBLASTOMA; HUMANS; OLIGOMYCINS; OXIDATIVE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84879788370     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.020     Document Type: Article

References (41)

1. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
2. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
3. Hitosugi T., Kang S., Vander Heiden M.G., Chung T.W., Elf S., Lythgoe K., Dong S., Lonial S., Wang X., Chen G.Z., Xie J., Gu T.L., Polakiewicz R.D., Roesel J.L., Boggon T.J., Khuri F.R., Gilliland D.G., Cantley L.C., Kaufman J., Chen J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:ra73.
4. Vander Heiden M.G., Locasale J.W., Swanson K.D., Sharfi H., Heffron G.J., Amador-Noguez D., Christofk H.R., Wagner G., Rabinowitz J.D., Asara J.M., Cantley L.C. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329:1492-1499.
5. Stopschinski B.E., Beier C.P., Beier D. Glioblastoma cancer stem cells - from concept to clinical application. Cancer Lett. 2012.
6. Kanu O.O., Hughes B., Di C., Lin N., Fu J., Bigner D.D., Yan H., Adamson C. Glioblastoma multiforme oncogenomics and signaling pathways. Clin. Med. Oncol. 2009, 3:39-52.
7. Squatrito M., Holland E.C. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res. 2011, 71:5945-5949.
8. Griguer C.E., Oliva C.R., Gillespie G.Y. Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J. Neurooncol. 2005, 74:123-133.
9. Jelluma N., Yang X., Stokoe D., Evan G.I., Dansen T.B., Haas-Kogan D.A. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol. Cancer Res. 2006, 4:319-330.
10. Zhu Z., Jiang W., McGinley J.N., Thompson H.J. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 2005, 65:7023-7030.
11. Prasanna V.K., Venkataramana N.K., Dwarakanath B.S., Santhosh V. Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma. J. Cancer Res. Ther. 2009, 5(Suppl. 1):S44-47.
12. Egler V., Korur S., Failly M., Boulay J.L., Imber R., Lino M.M., Merlo A. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin. Cancer Res. 2008, 14:3132-3140.
13. Beckner M.E., Gobbel G.T., Abounader R., Burovic F., Agostino N.R., Laterra J., Pollack I.F. Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab. Invest. 2005, 85:1457-1470.
14. Zhou W., Mukherjee P., Kiebish M.A., Markis W.T., Mantis J.G., Seyfried T.N. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr. Metab. (Lond.) 2007, 4:5.
15. Wolf A., Agnihotri S., Micallef J., Mukherjee J., Sabha N., Cairns R., Hawkins C., Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 2011, 208:313-326.
16. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
17. Gross S., Cairns R.A., Minden M.D., Driggers E.M., Bittinger M.A., Jang H.G., Sasaki M., Jin S., Schenkein D.P., Su S.M., Dang L., Fantin V.R., Mak T.W. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 2010, 207:339-344.
18. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
19. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465:966.
20. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
21. Hardie D.G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011, 25:1895-1908.
22. Inoki K., Kim J., Guan K.L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 2012, 52:381-400.
23. Davies S.P., Sim A.T., Hardie D.G. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur. J. Biochem. 1990, 187:183-190.
24. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
25. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
26. Okoshi R., Ozaki T., Yamamoto H., Ando K., Koida N., Ono S., Koda T., Kamijo T., Nakagawara A., Kizaki H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem. 2008, 283:3979-3987.
27. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
28. Hao W., Chang C.P., Tsao C.C., Xu J. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J. Biol. Chem. 2010, 285:12647-12654.
29. Nunez Rodriguez N., Lee I.N., Banno A., Qiao H.F., Qiao R.F., Yao Z., Hoang T., Kimmelman A.C., Chan A.M. Characterization of R-ras3/m-ras null mice reveals a potential role in trophic factor signaling. Mol. Cell. Biol. 2006, 26:7145-7154.
30. Kimmelman A.C., Qiao R.F., Narla G., Banno A., Lau N., Bos P.D., Nunez Rodriguez N., Liang B.C., Guha A., Martignetti J.A., Friedman S.L., Chan A.M. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 2004, 23:5077-5083.
31. Gallagher E.J., LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann. N. Y. Acad. Sci. 2011, 1243:54-68.
32. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
33. Hirschhaeuser F., Sattler U.G., Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011, 71:6921-6925.
34. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
35. Ishii N., Tada M., Hamou M.F., Janzer R.C., Meagher-Villemure K., Wiestler O.D., Tribolet N., Van Meir E.G. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 1999, 18:5870-5878.
36. Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
37. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
38. Godlewski J., Nowicki M.O., Bronisz A., Nuovo G., Palatini J., De Lay M., Van Brocklyn J., Ostrowski M.C., Chiocca E.A., Lawler S.E. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 2010, 37:620-632.
39. Svensson K.J., Kucharzewska P., Christianson H.C., Skold S., Lofstedt T., Johansson M.C., Morgelin M., Bengzon J., Ruf W., Belting M. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc. Natl. Acad. Sci. USA 2011, 108:13147-13152.
40. Lino M.M., Merlo A. PI3Kinase signaling in glioblastoma. J. Neurooncol. 2011, 103:417-427.
41. Mendez O., Zavadil J., Esencay M., Lukyanov Y., Santovasi D., Wang S.C., Newcomb E.W., Zagzag D. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol. Cancer 2010, 9:133.